- Home
- BCAT vs TRVI Comparison
BCAT vs TRVI Comparison
Compare BCAT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | TRVI |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BCAT | TRVI |
|---|---|---|
| Price | $14.62 | $11.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | 728.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.91 | $4.85 |
| 52 Week High | $15.41 | $14.39 |
Technical Indicators
Market Signals| Indicator | BCAT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 43.88 |
| Support Level | $14.64 | $10.04 |
| Resistance Level | $14.84 | $11.78 |
| Average True Range (ATR) | 0.18 | 0.73 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 0.65 | 8.00 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.